Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Is There a Possible Comeback for Nektar Therapeutics?

February 18, 2021 0

Nektar Therapeutics YoYoing Stock Price Investors who exaggerate their enthusiasm, or their apathy, towards buying and …

Vir Biotechnology and GlaxoSmithKline Expanded Agreement

February 17, 2021 0

Vir Biotechnology and GlaxoSmithKline Expanded Collaboration Vir Biotechnology (VIR) and GlaxoSmithKline plc (GSK) announced the signing …

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

February 17, 2021 0

bluebird bio Suspends LentiGlobin Studies bluebird bio (BLUE) placed its Phase 1/2 (HGB-206) and Phase 3 …

Regeneron Has Much Good News. Is the Market Paying Attention?

February 12, 2021 0

Regeneron Pharmaceuticals Approval of EvkeezaTM for HoFH Regeneron Pharmaceuticals (REGN) has a series of good news …

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

February 10, 2021 2

Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. (SAVA) - a clinical-stage biotech firm focused on …

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

February 8, 2021 0

Cassava Sciences 2021 Focus and Momentum Cassava Sciences (SAVA) President & CEO, Remi Barbier, informed that …

Researchers at the Children’s Hospital of Philadelphia are Improving Gene Therapy Vectors

February 5, 2021 0

The Children’s Hospital of Philadelphia: Improving Gene Therapy Vectors Improving gene therapy vectors seems to have …

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

February 5, 2021 0

Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for …

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer’s Patients Following Six Months of Treatment

February 2, 2021 2

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences (SAVA) announced impressive results of an interim …

Amgen is Still the King of the Biotech Sector

January 30, 2021 0

Amgen KRAS Inhibitor, Sotorasib Amgen (AMGN) has taken on one of the toughest challenges in the last …

Moderna COVID-19 Vaccine Produced Neutralizing Titers Against Key Emerging Variants Tested

January 28, 2021 0

Moderna COVID-19 Vaccination News A vaccination with the Moderna (MRNA) COVID-19 produced neutralizing titers against all …

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

January 28, 2021 0

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals (CASI) partner BioInvent …

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

January 14, 2021 0

bluebird bio Decision to Separate its Businesses bluebird bio (BLUE) will retain focus on its severe genetic …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Is There a Possible Comeback for Nektar Therapeutics?

Vir Biotechnology and GlaxoSmithKline Expanded Agreement

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

Regeneron Has Much Good News. Is the Market Paying Attention?

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Researchers at the Children’s Hospital of Philadelphia are Improving Gene Therapy Vectors

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer’s Patients Following Six Months of Treatment

Amgen is Still the King of the Biotech Sector

Moderna COVID-19 Vaccine Produced Neutralizing Titers Against Key Emerging Variants Tested

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

Aurinia Pharmaceuticals: FDA Approved LUPKYNIS for Active Lupus Nephritis in Adults

Merck Has Interesting News and Impressive Results

ViiV Healthcare: The FDA Approved Cabenuva for Adults Who are HIV Virologically-Suppressed

Exelixis: The FDA Approved Cabometyx in Combination with Opdivo as a First Line Treatment of RCC

Compugen: Why the Great Expectations from this Firm

Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

News About Reata Pharmaceuticals

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms